Bionano Genomics, Inc. (BNGO) financial statements (2020 and earlier)

Company profile

Business Address 9540 TOWNE CENTRE DRIVE
SAN DIEGO, CA 92121
State of Incorp. DE
Fiscal Year End December 31
SIC 3826 - Laboratory Analytical Instruments (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1717
Cash and cash equivalents1717
Receivables65
Inventory, net of allowances, customer advances and progress billings31
Inventory31
Prepaid expense11
Other current assets00
Total current assets:2823
Noncurrent Assets
Property, plant and equipment22
Total noncurrent assets:22
TOTAL ASSETS:3025
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities64
Accounts payable31
Accrued liabilities33
Deferred revenue0
Debt20 
Other undisclosed current liabilities 0
Total current liabilities:265
Noncurrent Liabilities
Long-term debt and lease obligation 9
Long-term debt, excluding current maturities 9
Liabilities, other than long-term debt01
Deferred revenue0
Other liabilities01
Other undisclosed noncurrent liabilities 0
Total noncurrent liabilities:010
Total liabilities:2715
Stockholders' equity
Stockholders' equity attributable to parent410
Common stock00
Additional paid in capital10683
Accumulated deficit(103)(73)
Total stockholders' equity:410
TOTAL LIABILITIES AND EQUITY:3025

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
Revenues1012
Cost of revenue
(Cost of Goods and Services Sold)
(7)(9)
Gross profit:33
Operating expenses(29)(24)
Operating loss:(26)(20)
Nonoperating income (expense)(4)2
Other nonoperating expense(0)(1)
Interest and debt expense(1)(0)
Loss from continuing operations before equity method investments, income taxes:(31)(19)
Other undisclosed income from continuing operations before income taxes10
Loss from continuing operations before income taxes:(30)(18)
Income tax expense(0)(0)
Net loss available to common stockholders, diluted:(30)(18)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
Net loss:(30)(18)
Comprehensive loss, net of tax, attributable to parent:(30)(18)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: